GlassScriptPhysician profile
Andrew R Colin
NPI 1104853688
$31,510.00
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $2,631 · 2021: $4,774 · 2022: $247.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor (International) LTD. | $14,122.87 | 2019 | |
| Glaxosmithkline, LLC. | $7,929.85 | 2019 | |
| Sanofi Pasteur INC. | $7,593.91 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $661.68 | 2019-2020 | |
| Insmed, INC. | $336.06 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $247.81 | 2021-2022 | |
| Gilead Sciences, INC. | $246.09 | 2019 | |
| Genentech USA, INC. | $124.77 | 2019 | |
| Amgen INC. | $123.29 | 2022 | |
| Sobi, INC | $77.52 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $24.93 | 2019 | |
| Chiesi USA, INC. | $21.22 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Colin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.